VBL Therapeutics (VBLT) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
VBL Therapeutics Announces Second Quarter 2015 Financial Results and Provides Business Update
August 13, 2015 8:00 AM EDT-- Reported Strengthened, Statistically Significant Interim Data From VB-111 Phase 2 Study in rGBM -- -- Reported Clinically Meaningful Interim Data From VB-111 Phase 1/2a Study in Platinum-Resistant Ovarian Cancer -- -- Presented Data on Proprietary Gene Therapy Vascular Targeting System -- -- Announces Successful Pre-Clinical Trial Application (CTA) Meeting With Health Canada --
TEL AVIV, Israel, Aug. 13, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT), a clinical-stage biotechnology company... More
